Efficacy of a slow-release formulation of lanreotide (Autogel®120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study
| Autor: | Paola Loli, Paolo Beck-Peccoz, P. F. Boscani, Maura Arosio, Silvia Grottoli, Marica Arvigo, M. Boschetti, E. C. Degli Uberti, G. Lombardi, G. Tamburrano, Cristina L. Ronchi, Gabriella Angeletti, Stefano Mariotti |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Longitudinal study
medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Octreotide medicine.disease Lanreotide Clinical trial Subcutaneous injection chemistry.chemical_compound Endocrinology Somatostatin chemistry Tolerability Internal medicine Acromegaly medicine business medicine.drug |
| Zdroj: | Clinical Endocrinology. 67:512-519 |
| ISSN: | 0300-0664 |
| DOI: | 10.1111/j.1365-2265.2007.02917.x |
| Popis: | Summary Objective Lanreotide Autogel® 120 mg (ATG120; Ipsen S.p.A, Milan, Italy) is a high-dose, sustained-release aqueous gel formulation, supplied in a prefilled syringe and given by deep subcutaneous injection. The aim of this study was to compare efficacy and tolerability of ATG120 given every 4–8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks. Design patients and intervention A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male). All patients had received o-LAR for 6–18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1). Then the interval between ATG120 injections was adjusted according to three different schemes: every 4, 6 or 8 weeks depending on GH levels (GH > 2·5 µg/l; 1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text